Transcat, Inc.

NASDAQ:TRNS

Industrial - Distribution

Industrials
$100.12 +2.19%

+$2.00 today

Market cap
$941.61M
Beta
0.70
P/E (TTM)
150.2
EPS (TTM)
$0.62
52W Low $50.23High $94.76

Volume 0.11M

Average 0.16M

TRNS Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Transcat, Inc.NASDAQ: TRNS

Research & Development · Q3 FY2026 · quarter ended Dec 2025

Research & development remains negative

Q3 FY2026 research & development was $0, compared with $0 a year earlier. Trailing-twelve-month research & development was $0.

Context

  • Research & development amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
  • Research & development increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly research & development holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterDec 2025
$0— QoQ
Last fiscal yearMar 2026
$0— YoY
LTMMar 2026
$0— YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—

Research & Development vs competitors

How TRNS compares with its peers on the latest reported figures

  • TRNS's LTM Mar 2026 research & development of $0 is the 9th highest of the 11 companies compared; the peer median is $30.32M.
  • Research & development amounts to 0.0% of revenue for TRNS, versus a peer median of 6.0%.
TRNS Competitors Peer median
Research & Development for TRNS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BIOBio-Rad Laboratories, Inc.LTM Jun 2026$261.1M -14.3%+0.0%10.1%
MTDMettler-Toledo International Inc.LTM Jun 2026$208.01M +7.9%+4.0%5.0%
QDELQuidelOrtho CorporationLTM Mar 2026$177.9M -16.4%-0.3%6.7%
TECHBio-Techne CorporationLTM Sep 2026$96.87M -3.0%+0.8%7.9%
NEONeoGenomics, Inc.LTM Jun 2026$38.17M +9.5%+6.9%5.0%
LABStandard BioTools Inc.LTM Mar 2026$22.48M -43.6%-11.4%26.1%
BLFSBioLife Solutions, Inc.LTM Mar 2026$8.14M +5.5%-20.0%8.2%
TKNOAlpha Teknova, Inc.LTM Mar 2026$2.25M -8.0%-34.3%5.4%
TRNSTranscat, Inc.LTM Mar 2026$0 ——0.0%
UFPTUFP Technologies, Inc.LTM Jun 2026$0 ——0.0%
TICTIC Solutions, Inc.LTM Jun 2026$0 ——0.0%
Peer median (excluding TRNS) $30.32M-5.5%-0.2%6.0%

Competitors are the stored peer set for TRNS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Mar 2022
FY2022
Mar 2023
FY2023
Mar 2024
FY2024
Mar 2025
FY2025
Mar 2026
Revenue204.96M230.57M259.48M278.42M331.88M
Cost of Revenue146.52M162.21M175.68M188.97M223.57M
Gross Profit58.44M68.36M83.81M89.45M108.3M
Gross Margin28.5%29.6%32.3%32.1%32.6%
Research & Development00000
Selling, General & Admin44.3M52.11M64.03M71.58M95.04M
Operating Expenses44.3M52.11M64.03M71.58M95.04M
Depreciation & Amortization9.57M10.96M13.54M18.57M26.17M
EBITDA23.57M26.86M33.82M37.69M38.76M
EBITDA Margin11.5%11.6%13.0%13.5%11.7%
Operating Income14.14M16.25M19.78M17.87M13.26M
Operating Margin6.9%7.0%7.6%6.4%4.0%
Interest Income00808K825K0
Interest Expense810K2.42M1.84M798K5.27M
Other Income / Expenses(953K)(2.76M)(1.34M)452K(5.27M)
Income Before Tax13.19M13.49M18.44M18.33M7.99M
Pre-Tax Margin6.4%5.8%7.1%6.6%2.4%
Income Tax Expense1.81M2.8M4.79M3.81M2.61M
Net Income11.38M10.69M13.65M14.52M5.38M
Net Margin5.6%4.6%5.3%5.2%1.6%
EPS (Basic)1.521.421.661.580.58
EPS (Diluted)1.501.401.631.570.57
Weighted Avg Shares7.5M7.55M8.24M9.19M9.33M
Weighted Avg Shares (Diluted)7.59M7.65M8.35M9.25M9.33M

Transcat, Inc.

NASDAQ:TRNS

Intrinsic Alpha fair value

Locked

Current Price

$100.12

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.